January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion ImmunoOncology Deal In yet

First Page		Document Content
Date: 2016-01-11 11:16:23 Business Biotechnology Economy Pharmacy Pharmaceutical industry Pharmaceuticals policy Biopharmaceutical Pharmaceutical industry in India Novartis Biosimilar Boehringer Ingelheim Teva Pharmaceutical Industries		January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion ImmunoOncology Deal In yet Add to Reading List Source URL: www.dcat.org Download Document from Source Website File Size: 310,19 KB Share Document on Facebook

	Global Discovery to Development Innovation Forum - Speaker Bio Andreas Gollner - Research Group Leader Medicinal Chemistry - Boehringer Ingelheim PhD: University of Vienna (Organic Chemistry) Post Doc at Columbia Univer DocID: 1uA19 - View Document
	Microsoft Word - Boehringer Ingelheim 2010 ltr v2.doc DocID: 1ubPw - View Document
	January 3, 2017 Immediately Keri McGrath Happe; ; +Lauren Zierke; ; +Elanco Animal Health Completes Acquisition of Boehringer Ingelheim DocID: 1tQb1 - View Document
	Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. T DocID: 1skMX - View Document
	Reasons for CRADA Delays In the Past Ongoing • Sponsors hesitant and not DocID: 1rqkp - View Document